This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.
Ziopharm (ZIOP) Down on Workforce Reduction Announcement
by Zacks Equity Research
Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.
Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?
by Zacks Equity Research
Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Ziopharm (ZIOP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ziopharm (ZIOP) stock based on the movements in the options market lately.
Do Options Traders Know Something About Ziopharm Oncology (ZIOP) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Ziopharm Oncology (ZIOP) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock
by Zacks Equity Research
Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.
Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
by Zacks Equity Research
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.
Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Ziopharm Oncology (ZIOP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in Ziopharm Oncology (ZIOP) Stock?
by Zacks Equity Research
Ziopharm Oncology (ZIOP) needs investors to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in ZIOPHARM Oncology (ZIOP) Stock?
by Zacks Equity Research
Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.
Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges
by Zacks Equity Research
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.
Ziopharm Oncology (ZIOP) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ziopharm (ZIOP) delivered earnings and revenue surprises of -18.18% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.
Ziopharm Oncology (ZIOP) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Ziopharm (ZIOP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for ZIOPHARM Oncology (ZIOP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in ZIOPHARM Oncology (ZIOP) Stock?
by Zacks Equity Research
Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.
Intrexon Reports Preliminary Earnings and Revenues for Q2
by Zacks Equity Research
Intrexon (XON) reports preliminary second-quarter 2018 results and expects a loss of 17 cents for the quarter.
Ziopharm Oncology (ZIOP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ziopharm (ZIOP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
by Zacks Equity Research
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Intrexon's (XON) loss in the fourth quarter of 2017 was narrower than expected.
CAR-T Therapy Space 2017 Progress Report
by Zacks Equity Research
Given the vast potential of the CAR T therapy space and two recent approvals, biotech companies are leaving no stone unturned to develop their pipeline candidates.
Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Intrexon (XON) reported narrower-than-expected loss but revenues missed estimates in the third quarter of 2017. The company remains focused on the development of its pipeline candidates.
Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider
by Arpita Dutt
Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?
Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus
by Zacks Equity Research
With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.